Publicly listed drug manufacturer, IBN SINA Pharmaceutical Industry Ltd has reported a modest growth in its earnings for the fiscal year 2022, that in turn yielded an increase in the company’s dividend payout.
The company made the announcement on Tuesday at the exchange website after holding a board meeting on Monday.
According to the disclosure, IBN SINA Pharma witnessed a growth of 23.8% on its earnings per share that stood at Tk19.39 for the fiscal year.
During the April-June quarter, the company earned Tk6.13 per share, which was Tk4.74 during the same period in the previous year.
The company’s board of directors recommended a cash dividend of 60% for the 2022 fiscal year, which is higher than previous year’s 47%.
Record date for the cash dividend has been set on September 29.
In addition, the board has also approved purchasing a land measuring 27 decimals located at Zhilanzha Mauza, Cox's Bazar Sadar, Cox's Bazar, costing Tk2.30 crore, excluding registration and other related expenses.
The land will be used for constructing a sales depot and training center of the company, added the disclosure.
Furthermore, the company has also decided to transfer a part of its net assets from the Natural Medicine Division worth Tk20.8 crore to its 99.9% owned subsidiary company named IBN SINA Natural Medicine Ltd for better management and ease of operation of its natural medicine production.
Subsequently a Vendors Agreement to be executed between the companies for facilitating the asset transfer in exchange of consideration other than cash as against acquiring shares held by the holding company.
Date for the annual general meeting has been fixed on October 30.
IBN SINA Pharmaceutical Industry Ltd was listed with the Dhaka bourse in the year 1989.



